For full experience: Flip your screen for the interactive congress.
Immune dysregulation and drug selection in #MDS
We spoke to Shahram Kordasti (@KingsCollegeLon) about the heterogenous immune environment seen in MDS and how to optimize drug selection: http://ow.ly/rj6750EF8Sr
@KordastiL #ESHMDS2021 @ESHaematology #HemOnc #MDSsm #ImmunoOnc
The 2021 #MDS armamentarium
Felicitas Thol discusses the current treatment landscape for high- and low-risk MDS: http://ow.ly/zPcY50EF8Fc
#ESHMDS2021 @ESHaematology #HemOnc #MDSsm
Tackling lower-risk MDS in 2021 - luspatercept, imetelstat & roxadustat.
Learn more with Valeria Santini of @UNI_FIRENZE: http://ow.ly/PEwV50EBtsO
#ESHMDS2021 @ESHaematology #HemOnc #MDSsm
For British Science Week 2021, we’re sharing talks from UK experts all week!
Today, hear from @KordastiL of @G_ICEMD on immune dysregulation and drug selection in #MDS:
http://ow.ly/YcFL50DQ3uw
#BSW21 @WeHCScientists @ScienceWeekUK #IAMRESILIENT2021 #ESHMDS2021 #HemOnc #MDSsm